| Document |
Document Title |
|
WO/2024/048438A1 |
The present invention addresses the problem of providing: a diastereomer preparation method whereby it becomes possible to produce a desired diastereomer from a diastereomer mixture with high efficiency; and a solid-phase photosensitizer...
|
|
WO/2024/032569A1 |
The present invention provides a prodrug compound, a preparation method therefor and a use thereof. Specifically, the present invention provides a compound represented by formula (I), a preparation method therefor, and a use thereof as a...
|
|
WO/2024/031002A1 |
This disclosure includes pesticidal compounds, compositions, and related agricultural methods.
|
|
WO/2023/223205A1 |
The present disclosure encompasses solid state forms of Mirdametinib, particularly to Mirdametinib complexes. In embodiments the present disclosure encompasses processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2023/217972A1 |
The invention relates to a novel method for producing chlorobenzaldehyde oximes of the general formula (I).
|
|
WO/2023/212071A1 |
Provided here is a method of treating a cancer in a subject in need thereof, comprising administering to said subject a combination comprising: (i) about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg,...
|
|
WO/2023/178256A1 |
The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib o...
|
|
WO/2023/178269A1 |
The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/170715A1 |
The present disclosure provides a compound of Formula (I), its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The present disclosure also provides a process for prepari...
|
|
WO/2023/160035A1 |
A β-elemene vinylation coupled derivative, and a preparation method therefor and the use thereof in the preparation of an antitumor drug. Provided are a β-elemene vinylation coupled derivative having a structure as represented by formu...
|
|
WO/2023/160039A1 |
Disclosed in the present invention are a β-elemene derivative with an HDACi pharmacophore, and a preparation method therefor and the use thereof. Provided in the present invention are a β-elemene derivative with an HDACi pharmacophore ...
|
|
WO/2023/160011A1 |
Disclosed are a β‑Elemene derivative containing an N-OH bond, a preparation method therefor and a use thereof. The present invention provides a class of β‑Elemene derivatives containing an N-OH bond having the structure shown in fo...
|
|
WO/2023/144798A1 |
Certain embodiments of the invention provide ionizable lipids having optimized clearance properties. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising ionizable lipids, methods of making the lipid ...
|
|
WO/2023/118558A1 |
A method of preparing a compound of Formula (I) or salt thereof, with reduced carboxylic acid by-product production.
|
|
WO/2023/061101A1 |
Disclosed are an HDAC/MAO-B dual inhibitor, the preparation thereof, and an application in the preparation of a drug and neuroprotective antioxidant for preventing and treating related diseases by inhibiting monoamine oxidase and histone...
|
|
WO/2023/025854A1 |
The present invention relates to malonamide compounds of the formula (I) where the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of said ...
|
|
WO/2023/003468A1 |
The invention relates to the field of medicinal chemistry and pharmacology, specifically to novel inhibitors of histone deacetylase (HDAC), and to compositions, methods of making, and using them, for instance in the treatment of chronic ...
|
|
WO/2023/286855A1 |
The purpose of the present invention is to provide an excellent agricultural or horticultural plant disease control agent. Provided are: a formamide derivative represented by general formula [I] and the like (in the formula, X1, X2, X3...
|
|
WO/2022/266046A1 |
The technology described herein is directed to compositions and cell culture media for increasing the lifespan of neutrophils. Also described are methods and kits for culturing neutrophils using the compositions or cell culture media. Su...
|
|
WO/2022/237644A1 |
The present invention provides an oxime ester photoinitiator of a chalcone structure, a preparation method therefor and an application thereof. The initiator has the following structure: Ar1, wherein Ar2 is a substituent containing an ar...
|
|
WO/2022/229017A1 |
It is disclosed a compound being the adamantyl retinoid derivative (3-[3'-adamantan-1-yl-4'-(1-hydroxycarbamoylethoxy)-biphenyl
-4-yl]-acrylic acid) together with it enantiomers, racemic mixtures and salts having improved pharmacological...
|
|
WO/2022/218853A1 |
The invention relates to a novel method for producing chloro-benzaldehyde oximes of the general formula (I).
|
|
WO/2022/177557A1 |
The present disclosure relates to: a) crystalline forms of N-((R)-2,3-dihydroxypropoxy)- 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N-((R)-2,3-dihydr...
|
|
WO/2022/177556A1 |
The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo
-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystallin...
|
|
WO/2022/177555A1 |
The present disclosure relates to dispersible pharmaceutical compositions comprising N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo
-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2022/125620A1 |
There is currently a high demand for new therapeutic antibiotics with new mechanisms of action. Disclosed are two small molecules, tryglysin A and B, with novel chemical structures and potent antibiotic activity against a narrow spectrum...
|
|
WO/2022/038632A1 |
The present invention discloses novel nigericin derivatives of general formula (I) that exhibit low toxicity and inhibition activity against gram-positive bacteria, gram-negative bacteria, and viruses. The present invention also disclose...
|
|
WO/2021/252640A1 |
The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, interme...
|
|
WO/2021/209859A1 |
Monomers, polymers formed from such monomers, and articles for biomaterial capture including such polymers, wherein the monomer is represented by the following general Formula (I): CH2=CR1-C(=O)-X-R2-Z-X3-NR3-C(=X2)-X1-R4, wherein: R1 is...
|
|
WO/2021/117741A1 |
The purpose of the present invention is to provide a material for storing a gas (excluding nitrogen gas), e.g., hydrogen, carbon dioxide, methane, or acetylene, the material including a metal/organic framework having a hydroxamic acid gr...
|
|
WO/2021/102568A1 |
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2...
|
|
WO/2021/099929A1 |
The present invention relates to a process for the synthesis of hydroxamic acids by continuous flow process wherein said process comprising reacting alkyl ester with hydroxyl amine salt in presence of base in a microreactor system and co...
|
|
WO/2021/092174A1 |
The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylase (HCADC) (e.g., HDAC3) activity.
|
|
WO/2021/090194A1 |
The present invention provides methods for treating malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising aN-hydrox...
|
|
WO/2021/052353A1 |
The present invention relates to the technical field of enzyme inhibitors, and relates in particular to a hydroxamic acid derivative, a preparation method therefor and an application thereof. The hydroxamic acid group in the hydroxamic a...
|
|
WO/2021/046640A1 |
The present disclosure relates to new cannabinoid derivatives and precursors and catalytic asymmetric processes for their preparation. The disclosure also relates to pharmaceutical compositions and pharmaceutical and analytical uses of t...
|
|
WO/2021/044430A1 |
The present invention relates to compounds, compositions and methods for treating fibrosis. In particular, compounds that inhibit or downregulate Sirtuin 1 (SIRT1) activity, which are particularly useful in the treatment of Idiopathic Pu...
|
|
WO/2021/007190A1 |
A process for preparing and purifying a compound of Formula (I) is provided; or a salt thereof, wherein the subscript m is an integer of from 0 to 3; each Ra is independently selected from the group consisting of (C3-C8)cycloalkyl, (C1-C...
|
|
WO/2021/005294A1 |
The present invention relates to a compound of the following formula (I): H-CO-N(OH)-CH2-CH(R1)-CO-NH-(CH2)n-CH(R2)-(CH2)m-CO-R3 (I) as well as a pharmaceutically acceptable salt and/or solvate thereof. The present invention also relates...
|
|
WO/2020/254558A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2020/201089A1 |
The present invention relates to a complex comprising a transition metal cation (i); a ligand (ii) comprising at least one chelating group, preferably from 1 to 4 chelating groups, more preferred 2 or 3 chelating groups, wherein the chel...
|
|
WO/2020/198401A1 |
The disclosure provides a method of treating a malignant rhabdoid tumor in a subject in need thereof including administering to the subject a therapeutically-effective amount of (S)-N-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-c...
|
|
WO/2020/193431A1 |
The present invention relates to novel inhibitors of histone deacetylase 10 (HDAC10), novel pharmaceutical compositions comprising such inhibitors, and to novel methods of treating diseases, such as cancer, autoimmune disorders or neurod...
|
|
WO/2020/127924A1 |
The invention relates to a process for the preparation of Voxelotor, or a salt or solvate thereof, which comprises the use of a compound of formula (I) or (I'), or a salt or solvate thereof.
|
|
WO/2020/129900A1 |
The purpose of the present invention is to provide a method for industrially and efficiently producing a C-arylhydroxy glycoxide derivative at low cost. The present invention provides a method for producing a C-arylhydroxy glucoxide deri...
|
|
WO/2020/064818A1 |
Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process.
|
|
WO/2020/061367A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2020/061340A1 |
Included within the scope of the invention are methods of preparing a shelf-stable Formulation comprising mixing a solvent, at least one of a surfactant, a fabric conditioner, detersive agent (detergent), emulsifier, humectant, a coloran...
|
|
WO/2020/002238A1 |
The present invention provides compounds of formula (I) for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
|
